Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite challenges, including the delayed regulatory submissions of Itepekimab. The delay in Itepekimab’s approval ...

We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

--On pace for largest percent decrease since Oct. 27, 2023, when it fell 19.13% --Down 9.68% month-to-date; on pace for worst month since Oct. 2023, when it fell 15.64% --Down 16.48% from its all-time ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...